Abstract
Antimitotic chemotherapy remains the most effective approach to treat a variety of human neoplasms. Since the discovery of tubulin-targeting agents, vinca alkaloids and the taxanes including paclitaxel and docetaxel are used clinically to treat several solid tumors of the head and neck, breast, lung, ovary, and bladder. Despite the preclinical and clinical success of tubulin-targeting agents, the ability of tumors to develop an acquired resistance to drugs used for treatment and neurotoxicity severely limited their long-term effectiveness to cancer cure. Lately, advances in antimitotic treatments led to the identification of novel mitosis-specific agents that are expected to show higher selectivity and less cytotoxicity compared to known antimitotics. This review focuses on the progress of kinesin motor inhibitors that target proteins that function predominantly in mitosis.
Keywords: Antimitotics, Ispinesib, KSP kinesin, Mitotic kinesins, Neoplasms, Taxanes, Tubulin-targeting Agents, vinca alkaloids, paclitaxel
Reviews on Recent Clinical Trials
Title: Recent Advances of Kinesin Motor Inhibitors and their Clinical Progress
Volume: 6 Issue: 3
Author(s): Antiopi Voultsiadou and Vasiliki Sarli
Affiliation:
Keywords: Antimitotics, Ispinesib, KSP kinesin, Mitotic kinesins, Neoplasms, Taxanes, Tubulin-targeting Agents, vinca alkaloids, paclitaxel
Abstract: Antimitotic chemotherapy remains the most effective approach to treat a variety of human neoplasms. Since the discovery of tubulin-targeting agents, vinca alkaloids and the taxanes including paclitaxel and docetaxel are used clinically to treat several solid tumors of the head and neck, breast, lung, ovary, and bladder. Despite the preclinical and clinical success of tubulin-targeting agents, the ability of tumors to develop an acquired resistance to drugs used for treatment and neurotoxicity severely limited their long-term effectiveness to cancer cure. Lately, advances in antimitotic treatments led to the identification of novel mitosis-specific agents that are expected to show higher selectivity and less cytotoxicity compared to known antimitotics. This review focuses on the progress of kinesin motor inhibitors that target proteins that function predominantly in mitosis.
Export Options
About this article
Cite this article as:
Voultsiadou Antiopi and Sarli Vasiliki, Recent Advances of Kinesin Motor Inhibitors and their Clinical Progress, Reviews on Recent Clinical Trials 2011; 6 (3) . https://dx.doi.org/10.2174/157488711796575522
DOI https://dx.doi.org/10.2174/157488711796575522 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeting Ion Channels for New Strategies in Cancer Diagnosis and Therapy
Current Clinical Pharmacology The Role of Integrins in Glioma Biology and Anti-Glioma Therapies
Current Pharmaceutical Design Synthesis and Biological Evaluation of 2´-Hydroxy-4´,6´-Diprenyloxychal-Cone Derivatives as Potent CDC25B and PTP1B Inhibitors
Letters in Drug Design & Discovery VEGF/VEGFR2 Autocrine Signaling Stimulates Metastasis in Prostate Cancer Cells
Current Angiogenesis (Discontinued) Metallothioneins and Platinum(II) Anti-Tumor Compounds
Current Medicinal Chemistry Regulation of EMT by Notch Signaling Pathway in Tumor Progression
Current Cancer Drug Targets Targeting CCK Receptors in Human Cancers
Current Topics in Medicinal Chemistry Antitumor Activity of Titanocene Y in Xenografted PC3 Tumors in Mice
Letters in Drug Design & Discovery STAT3 Activation in Circulating Monocytes Contributes to Neovascular Age-Related Macular Degeneration
Current Molecular Medicine Role of Iodine, Selenium and Other Micronutrients in Thyroid Function and Disorders
Endocrine, Metabolic & Immune Disorders - Drug Targets Emerging Strategies and Challenges for Controlled Delivery of Taxanes: A Comprehensive Review
Current Drug Metabolism Nanotechnology Applications for Diffuse Intrinsic Pontine Glioma
Current Neuropharmacology Patents in Cancer Stem Cells
Recent Patents on Biomarkers Artificial Intelligence, Big Data and Machine Learning Approaches in Precision Medicine & Drug Discovery
Current Drug Targets Anti-VEGF Anticancer Drugs: Mind the Hypertension
Recent Advances in Cardiovascular Drug Discovery (Discontinued) Chronobiology of the Neuroimmunoendocrine System and Aging
Current Pharmaceutical Design Curcuminoid Metabolism and its Contribution to the Pharmacological Effects
Current Drug Metabolism Identification and Characterization of New Proteins in Podocyte Dysfunction of Membranous Nephropathy by Proteomic Analysis of Renal Biopsy
Current Pharmacogenomics and Personalized Medicine The Role of CD40 Expression in Dendritic Cells in Cancer Biology; A Systematic Review
Current Cancer Drug Targets Human Growth Hormone Induced Cholestatic Hepatitis in a Growth Hormone Deficient Patient with Short Stature
Current Drug Safety